Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$152.42 USD
+2.32 (1.55%)
Updated Feb 4, 2025 04:00 PM ET
After-Market: $152.42 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum C VGM
Price, Consensus and EPS Surprise
NBIX 152.42 +2.32(1.55%)
Will NBIX be a Portfolio Killer in February?
Zacks Investment Research is releasing its prediction for NBIX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NBIX
Neurocrine (NBIX) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
NBIX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Q4 Release
Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now?
Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This Strength Last?
Other News for NBIX
Neurocrine Biosciences Q4 Earnings Preview: What To Expect After The New Drug Approval
Neurocrine price target raised to $184 from $182 at BofA
Neurocrine price target raised by $2 at BofA, here's why
Neurocrine price target raised to $185 from $170 at Morgan Stanley
Neurocrine price target raised by $15 at Morgan Stanley, here's why